PBAC accused of ‘bullying’ drug companies into giving free drugs

Uncertainty for migraine patients and pharmacists is likely to persist as Novartis pulls PBS application for Aimovig This week Novartis decided to no longer proceed with a third Aimovig (erenumab) submission to the PBAC and seek PBS reimbursement for the prevention of migraine in eligible patients. Richard Tew, general manager of Novartis Pharmaceuticals Australia and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Wanted: new chief for Gold Cross
Next New listings